Kunyi Zhang1, Lijuan Gao1, Yuqi Wu1, Jianyi Chen1, Chengguang Lin1, Shaohua Liang1, Jianxin Su1, Jinming Ye2, Xuyu He3. 1. Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Department of Radiation Oncology, Cancer Center, Sun Yat-Sen University Guangzhou 510060, People's Republic of China. 2. Internal Medicine, Guangdong Provincial Police Hospital No. 88 West Shitan Road, Guangzhou 510430, PR. China. 3. Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences 106 Zhongshan Road 2, Guangzhou 510080, China.
Abstract
PURPOSE: To investigate the association between the N-acetyltransferase 1 (NAT1) slow and rapid acetylation phenotypes with cancer risk based on a meta-analysis. METHODS: Previously published case-control studies were retrieved from PubMed, Embase, and Web of Science. Odds ratios (ORs) with 95% confidence intervals (CIs) were determined to assess the relationship between NAT1 polymorphisms and cancer risk. RESULTS: A total of 73 studies (24874 cases and 30226 controls) were included in this meta-analysis. No significant association was identified between NAT1 polymorphisms (slow acetylation versus rapid acetylation genotypes: OR = 0.978, 95% CI = 0.927-1.030, P < 0.001 for heterogeneity, I(2) = 45.5%) and cancer risk, whereas a significantly reduced risk of pancreatic cancer was identified in individuals with NAT1 slow acetylation genotype (OR = 0.856, 95% CI = 0.733-0.999, P =0.509 for heterogeneity, I(2) = 0). When the NAT1 slow acetylation genotype was analysed on the basis of stratified analyses of ethnicity, a significantly reduced risk of head and neck cancers was found among Asian (OR=0.281, 95% CI = 0.127-0.622). When the NAT1 slow acetylation genotype was analysed on the basis of stratified analyses of source of control, only significantly reduced risks of colorectal cancer (OR = 0.882, 95% CI = 0.798- 0.974, P = 0.212 for heterogeneity, I(2) = 22.9) and pancreatic cancer (OR=0.856, 95% CI = 0.733-0.999, P = 0.509 for heterogeneity, I(2) = 0) were found among hospital-based studies. CONCLUSIONS: No significant association between the NAT1 polymorphisms and the risk of cancer was found except for pancreatic cancer.
PURPOSE: To investigate the association between the N-acetyltransferase 1 (NAT1) slow and rapid acetylation phenotypes with cancer risk based on a meta-analysis. METHODS: Previously published case-control studies were retrieved from PubMed, Embase, and Web of Science. Odds ratios (ORs) with 95% confidence intervals (CIs) were determined to assess the relationship between NAT1 polymorphisms and cancer risk. RESULTS: A total of 73 studies (24874 cases and 30226 controls) were included in this meta-analysis. No significant association was identified between NAT1 polymorphisms (slow acetylation versus rapid acetylation genotypes: OR = 0.978, 95% CI = 0.927-1.030, P < 0.001 for heterogeneity, I(2) = 45.5%) and cancer risk, whereas a significantly reduced risk of pancreatic cancer was identified in individuals with NAT1 slow acetylation genotype (OR = 0.856, 95% CI = 0.733-0.999, P =0.509 for heterogeneity, I(2) = 0). When the NAT1 slow acetylation genotype was analysed on the basis of stratified analyses of ethnicity, a significantly reduced risk of head and neck cancers was found among Asian (OR=0.281, 95% CI = 0.127-0.622). When the NAT1 slow acetylation genotype was analysed on the basis of stratified analyses of source of control, only significantly reduced risks of colorectal cancer (OR = 0.882, 95% CI = 0.798- 0.974, P = 0.212 for heterogeneity, I(2) = 22.9) and pancreatic cancer (OR=0.856, 95% CI = 0.733-0.999, P = 0.509 for heterogeneity, I(2) = 0) were found among hospital-based studies. CONCLUSIONS: No significant association between the NAT1 polymorphisms and the risk of cancer was found except for pancreatic cancer.
Authors: E Kampman; M L Slattery; J Bigler; M Leppert; W Samowitz; B J Caan; J D Potter Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-01 Impact factor: 4.254
Authors: Naoko Ishibe; Rashmi Sinha; David W Hein; Martin Kulldorff; Paul Strickland; Adrian J Fretland; Wong-Ho Chow; Fred F Kadlubar; Nicholas P Lang; Nathaniel Rothman Journal: Pharmacogenetics Date: 2002-03
Authors: Rayjean J Hung; Paolo Boffetta; Paul Brennan; Christian Malaveille; Agnès Hautefeuille; Francesco Donato; Umberto Gelatti; Massimiliano Spaliviero; Donatella Placidi; Angela Carta; Antonio Scotto di Carlo; Stefano Porru Journal: Int J Cancer Date: 2004-07-01 Impact factor: 7.396
Authors: Carmine S Leggett; Mark A Doll; Raúl A Salazar-González; Mariam R Habil; John O Trent; David W Hein Journal: Arch Toxicol Date: 2021-11-16 Impact factor: 5.153
Authors: Xiaoyan Zhang; Samantha M Carlisle; Mark A Doll; Robert C G Martin; J Christopher States; Carolyn M Klinge; David W Hein Journal: J Pharmacol Exp Ther Date: 2018-01-16 Impact factor: 4.030